TREATMENT OF ORGAN TRANSPLANT-RELATED LYMPHOMA

First described in organ transplant recipients in 1968, post-transplan t lymphoproliferative disorder (PTLD) remains an often devastating com plication of immunosuppression. Similar, if not identical, Epstein-Bar r virus (EBV)-associated B lymphoproliferations have since been descri bed in congenital and other acquired immunodeficiency states. Although PTLD is often morphologically indistinguishable from aggressive non-H odgkin's lymphoma, the pathogenesis, presentation, clinical course, an d management options differ significantly from those of classic NHL.